Get the Stockscreener App
98.75
0.50%
-0.50
After Hours:
98.75
Zimmer Biomet Holdings Inc stock is traded at $98.75, with a volume of 1.79M.
It is down -0.50% in the last 24 hours and up +13.77% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$99.25
Open:
$98.68
24h Volume:
1.79M
Relative Volume:
0.81
Market Cap:
$19.57B
Revenue:
$8.01B
Net Income/Loss:
$807.20M
P/E Ratio:
24.44
EPS:
4.0411
Net Cash Flow:
$1.13B
1W Performance:
+2.38%
1M Performance:
+13.77%
6M Performance:
-6.58%
1Y Performance:
-4.71%
1-Day Range:
$97.53
$99.70
1-Week Range:
$96.31
$99.70
52-Week Range:
$84.59
$114.44
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
98.75 | 19.67B | 8.01B | 807.20M | 1.13B | 4.0411 |
|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Vanguard Group Inc. Acquires 39,929 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $6.12 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
William Blair Initiates Zimmer Biomet Holdings at Market Perform - marketscreener.com
William Blair initiates Zimmer Biomet stock rating at Market Perform - Investing.com
ZIMMER BIOMET HOLDINGS, INC. SEC 10-K Report - TradingView
Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction - TipRanks
3 Reasons to Avoid ZBH and 1 Stock to Buy Instead - Finviz
Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance - MSN
Zimmer Biomet Launches Advancement for Hindfoot Fusion - Ortho Spine News
ZBH Investor Alert: Hagens Berman Investigates Zimmer Biomet (ZBH) Over Alleged Emerging Market Failures and "Inconsistent" Execution - PR Newswire
Zimmer Biomet outlines 2026 revenue growth of 1%–3% amid US sales force overhaul and innovation cycle - MSN
Zimmer Biomet, Paragon 28 announce commercial launch of curved TTC nail system - MassDevice
The Top 5 Analyst Questions From Zimmer Biomet's Q4 Earnings Call - Finviz
There May Be Reason For Hope In Zimmer Biomet Holdings' (NYSE:ZBH) Disappointing Earnings - Yahoo Finance
Institution Moves: Will Zimmer Biomet Holdings Inc outperform its industry peersWeekly Stock Report & Intraday High Probability Setup Alerts - baoquankhu1.vn
The Top 5 Analyst Questions From Zimmer Biomet’s Q4 Earnings Call - Yahoo Finance
ABN Amro Investment Solutions Sells 11,020 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet stock: Is Wall Street bullish or bearish? - MSN
Why Zimmer Biomet Holdings Inc. stock is favored by hedge fundsWeekly Gains Summary & Accurate Buy Signal Notifications - mfd.ru
Can Zimmer Biomet Holdings Inc. stock surprise with earnings upside2025 Valuation Update & Precise Trade Entry Recommendations - mfd.ru
Is Zimmer Biomet Holdings Inc. exposed to political riskPortfolio Growth Summary & High Return Trade Guides - mfd.ru
Why Zimmer Biomet Holdings Inc. stock could be next big winner2025 Major Catalysts & AI Powered Trade Plan Recommendations - mfd.ru
Zimmer Biomet (NYSE:ZBH) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Update Report: Is Zimmer Biomet Holdings Inc stock a value trap2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
ZBH.SW Zimmer Biomet (SIX) at CHF67.50 pre-market on volume spike: Feb 2026 outlook - Meyka
Zimmer Biomet Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Market Participants Recognise Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Earnings - 富途牛牛
Skylands Capital LLC Sells 20,100 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Sound Shore Management Inc CT Decreases Stake in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Johnson Investment Counsel Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Envestnet Asset Management Inc. Grows Stock Position in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026 - Citeline News & Insights
Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlight - GuruFocus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH) and OrganiGram Holdings (OGI) - The Globe and Mail
Zimmer Biomet (NYSE:ZBH) Beats Estimates, Lifts Russell 1000 Healthcare - Kalkine Media
Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced - Yahoo Finance
Citigroup Raises Price Target for Zimmer Biomet Holdings (ZBH) | - GuruFocus
Wells Fargo Raises Zimmer Biomet Holdings (ZBH) Price Target to $98 | ZBH Stock News - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock - MarketBeat
UBS Adjusts Price Target on Zimmer Biomet Holdings to $89 From $86, Maintains Sell Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Zimmer Biomet PT to $115 From $125, Maintains Buy Rating - marketscreener.com
Barclays Adjusts Zimmer Biomet PT to $100 From $104, Maintains Underweight Rating - marketscreener.com
ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum - Finviz
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 earnings call transcript - MSN
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 Earnings Call Transcript - Insider Monkey
Zimmer plans US salesforce reorganization - Yahoo Finance
Zimmer Biomet shares climb after fourth-quarter sales and earnings growth - AlphaStreet News
Zimmer Biomet Q4 Earnings Call Highlights - MarketBeat
Zimmer Biomet earnings beat Wall Street expectations - The Journal Gazette
Research Alert: CFRA Maintains Hold Rating On Shares Of Zimmer Biomet Holdings, Inc. - 富途牛牛
Zimmer: Q4 Earnings Snapshot - Shelton Herald
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):